Venus Remedies Ltd Hits Upper Circuit Amid Strong Buying Pressure

Strong Buying Pressure Drives Stock to Upper Circuit

On 18 Feb 2026, Venus Remedies Ltd’s shares hit the upper price band of ₹786.60, up ₹37.45 from the previous close, reflecting a 5.0% gain. This price movement represents the maximum permissible daily increase under the current price band of 5%. The stock outperformed the Pharmaceuticals & Biotechnology sector, which declined by 0.12%, and the Sensex, which fell 0.23% on the same day.

The intraday high touched ₹785.95, closely aligning with the closing price, signalling sustained demand throughout the trading session. Total traded volume stood at 15,634 shares (0.15634 lakh), generating a turnover of approximately ₹1.21 crore. Despite this, delivery volume on 17 Feb was notably lower at 392 shares, down 70.95% compared to the five-day average, indicating a decline in investor participation in terms of actual shareholding transfer.

Price and Volume Dynamics

The weighted average price for the day was skewed towards the lower end of the trading range, suggesting that most trades occurred closer to the day’s low of ₹749.15. However, the upward momentum was strong enough to push the stock to its circuit limit, highlighting aggressive buying interest from traders and short-term investors.

Venus Remedies is currently trading above all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — signalling a strong bullish trend across multiple timeframes. The stock has recorded consecutive gains over the past two days, delivering a cumulative return of 6.59% during this period.

Regulatory Freeze and Unfilled Demand

The stock’s upper circuit hit triggered an automatic regulatory freeze on further buying for the remainder of the trading session, restricting additional upward price movement. This freeze is a standard mechanism designed to curb excessive volatility and ensure orderly market conduct.

Despite the freeze, unfilled demand remains evident as the stock closed at the maximum allowable price, indicating that buyers were willing to pay even higher prices had the circuit not been in place. This latent demand could potentially fuel further gains in subsequent sessions, provided the company’s fundamentals and market conditions remain favourable.

Fundamental and Market Context

Venus Remedies Ltd operates within the Pharmaceuticals & Biotechnology sector, a space characterised by innovation-driven growth and regulatory complexities. The company’s market capitalisation stands at ₹1,020 crore, categorising it as a micro-cap stock. Despite its relatively modest size, Venus Remedies has demonstrated resilience and growth potential, as reflected in its current Mojo Score of 70.0 and a Mojo Grade of Buy, recently revised from Strong Buy on 1 Feb 2026.

The downgrade in grade suggests a slight moderation in outlook, possibly due to valuation concerns or near-term risks, but the overall recommendation remains positive. The company’s Market Cap Grade is 4, indicating a mid-tier valuation relative to its peers.

Technical Outlook and Investor Considerations

Technically, Venus Remedies’ sustained trading above all major moving averages confirms a robust uptrend. The recent consecutive gains and upper circuit hit reinforce the bullish sentiment among traders. However, the sharp drop in delivery volumes signals caution, as fewer investors are holding shares for the long term, potentially increasing volatility.

Liquidity remains adequate for moderate trade sizes, with the stock’s average traded value supporting transactions up to ₹0.03 crore without significant price impact. This liquidity profile is typical for micro-cap stocks, which often experience wider price swings due to lower volumes.

Outlook and Strategic Implications

Investors should weigh the strong technical momentum against the micro-cap nature of Venus Remedies, which can entail higher risk and volatility. The recent upper circuit hit signals strong short-term interest, but the decline in delivery volumes suggests that long-term conviction may be limited at present.

Given the company’s sector positioning and positive Mojo Grade, Venus Remedies remains an attractive candidate for investors seeking exposure to the Pharmaceuticals & Biotechnology space with growth potential. However, prudent risk management and close monitoring of volume trends and regulatory developments are advisable.

Overall, the stock’s performance on 18 Feb 2026 underscores a bullish phase driven by aggressive buying, but the regulatory freeze and unfilled demand highlight the need for cautious optimism as the market digests this momentum.

Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →